"Yunzhou Biosciences (Guangzhou) Co., Ltd. will lead the planning of Guangzhou's gene delivery institute, the first of its kind worldwide. The project is expected to be launched in the second half of this year." Huang Rui, vice president of Strategies of the company, said during a media interview held by the Information Office of Guangzhou Municipal People's Government on August 29.
(Photo: GDToday)
According to Huang, it is generally believed in the industry that gene medicine will be the third pillar supporting the biomedicine landscape, following small molecule drugs and macromolecular drugs including proteins and antibodies, while gene delivery is also one of the rising fields.
Tackling key problems in gene delivery, the institute will focus on basic research and translating findings into practical applications to achieve technological breakthroughs. It is expected to become a leading gene research center globally, providing sustained support for gene delivery and medicine development.
"Prof. He Xiaoshun at the Sun Yat-sen University (SYSU) has put forward the view of ‘organ medicine’ on the basis of the breakthroughs in ischemia-free heart transplantation, isolation treatment for organs, and in vitro diseased organ research platform," said Zhao Qiang, chief physician of the Department of Organ Transplant at the First Affiliated Hospital of SYSU.
He added that relevant industries of organ medicine are likely to promote the development of a vast medical market, which will improve organ research in Guangzhou or even nationwide. "It will also boost the growth of precision medicine, integrating drug R&D, efficacy prediction, mechanism discussion, prevention, and treatment for major diseases," said Zhao.
(Photo: Nanfang Daily)
"Guangzhou boasts a favorable business environment and abundant medical resources. Guangdong Hengrui Pharmaceuticals Co., Ltd. was founded in 2019 and now operates projects in the southern headquarters, R&D center and the industrialization base in China-Singapore Guangzhou Knowledge City, with a total investment of over 800 million RMB," said Zhou Ye, head of Strategies of Hengrui Medicine.
"Guangzhou is home to many colleges and universities. Our company has established a number of high-end innovation platforms in cooperation with local universities so that we can fully leverage the advantages of our competence, platforms, technology, and talents to conduct the nonclinical evaluation of new tech and transform them into practical applications," said Guo Jianmin, managing director of Guangdong Lewwin Pharmaceutical Research Institute Co.Ltd.
Author | Teria Wang (intern), Hannah
Editor | Olivia, Jasmine, James
